Abiomed, Inc. (ABMD) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Devices Branche. Der Hauptsitz des Unternehmens ist in Danvers, MA, United States. Der aktuelle CEO ist Michael Minogue.
ABMD hat IPO-Datum 1987-07-29, 2,003 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $17.18B.
Abiomed, Inc. is a medical device company specializing in the research, development, and commercialization of advanced cardiac support systems designed to assist or replace the pumping function of failing hearts. The company's flagship Impella product line comprises multiple percutaneous micro heart pump configurations, including the Impella 2.5, CP, 5.0, LD, 5.5, and RP models, which serve interventional cardiologists, cardiac surgeons, and critical care teams across various clinical settings. Additionally, Abiomed offers the Impella SmartAssist platform with integrated sensor technology, Impella Connect cloud-based remote monitoring, and the OXY-1 System for portable respiratory assistance, while developing next-generation solutions such as Impella ECP and preCARDIA. Founded in 1981 and headquartered in Danvers, Massachusetts, the company maintains a global commercial presence across North America, Europe, Asia-Pacific, and other international markets. As of December 2022, Abiomed operates as a subsidiary of Johnson & Johnson.
